Brief: Inhibikase Therapeutics Announces FDA Clinical Hold On Ikt-148009 Programs
07/11/2022 14:01
Nov 7 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES FDA CLINICAL HOLD ON
IKT-148009 PROGRAMS
* INHIBIKASE THERAPEUTICS INC - FDA INDICATED IT WILL
PROVIDE AN
OFFICIAL CLINICAL HOLD LETTER TO INHIBIKASE WITHIN 30 DAYS
* INHIBIKASE THERAPEUTICS INC - ACTIVELY WORKING WITH FDA TO
UNDERSTAND AGENCY'S CONCERNS AND TO RESOLVE THEM AS SOON AS
POSSIBLE
* INHIBIKASE THERAPEUTICS INC - HAVE NOT SEEN ANY SERIOUS
ADVERSE
EVENTS IN ONGOING 201 TRIAL
Source text for Eikon: ID:nPn6dsx63a
Further company coverage: IKT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share